ZymoGenetics reports OS data for IL-21 in melanoma

ZymoGenetics Inc. (NASDAQ:ZGEN) said IL-21 produced a median overall survival of 12.4 months, with 53% of patients alive at 12 months, in a Phase IIa trial to treat metastatic melanoma. ZymoGenetics p...